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Background. Acute bacterial meningitis (ABM) in adults residing in resource-poor countries is associated with mortality rates 
>50%. To improve outcome, interventional trials and standardized clinical algorithms are urgently required. To optimize these pro-
cesses, we developed and validated an outcome prediction tool to identify ABM patients at greatest risk of death.
Methods. We derived a nomogram using mortality predictors derived from a logistic regression model of a discovery database 
of adult Malawian patients with ABM (n  =  523 [65%] cerebrospinal fluid [CSF] culture positive). We validated the nomogram 
internally using a bootstrap procedure and subsequently used the nomogram scores to further interpret the effects of adjunctive 
dexamethasone and glycerol using clinical trial data from Malawi.
Results. ABM mortality at 6-week follow-up was 54%. Five of 15 variables tested were strongly associated with poor outcome 
(CSF culture positivity, CSF white blood cell count, hemoglobin, Glasgow Coma Scale, and pulse rate), and were used in the deri-
vation of the Malawi Adult Meningitis Score (MAMS) nomogram. The C-index (area under the curve) was 0.76 (95% confidence 
interval, .71–.80) and calibration was good (Hosmer-Lemeshow C-statistic = 5.48, df = 8, P = .705). Harmful effects of adjunctive 
glycerol were observed in groups with relatively low predicted risk of poor outcome (25%–50% risk): Case Fatality Rate of 21% in the 
placebo group and 52% in the glycerol group (P < .001). This effect was not seen with adjunctive dexamethasone.
Conclusions. MAMS provides a novel tool for predicting prognosis and improving interpretation of ABM clinical trials by risk 
stratification in resource-poor settings. Whether MAMS can be applied to non-HIV-endemic countries requires further evaluation.
Keywords. bacterial meningitis, HIV, Africa, outcome, severity score.
 
Acute bacterial meningitis (ABM) in sub-Saharan Africa is 
common and associated with high rates of death and comor-
bidity in both adults and children [1, 2]. Throughout the 
African continent, bacterial meningitis is predominately 
caused by Streptococcus pneumoniae [3–5], with the exception 
of the “meningitis belt” Sahel region, where seasonal epidemic 
meningococcal meningitis also occurs [6]. In Malawi, the inci-
dence of ABM in adults is 12 per 100 000, and the associated 
mortality is 54% compared with 20%–30% in Europe and the 
United States [1, 2, 7, 8]. Despite intensive efforts, high mor-
tality remains unchanged region-wide; adjunctive treatments 
such as corticosteroids and glycerol are ineffective and possibly 
harmful [9–12].
To improve ABM outcome, interventional trials testing new 
treatment approaches and resource-appropriate standardized 
clinical algorithms are urgently required. A  robust outcome 
prediction tool would help optimize these processes and pro-
vide a basis to examine why previous adjunctive interventions 
have been unsuccessful [13].
Well-validated scores used for risk stratification in life-threat-
ening infection include Confusion Urea Respiratory Rate age 65 
(CURB-65) for pneumonia, and Acute Physiology And Chronic 
Health Evaluation (APACHE II) and Sepsis-related Organ 
Failure Assessment (SOFA) for sepsis [14–17]. Two good-qual-
ity scores have been reported for ABM in developed settings 
[18, 19]. A meningitis score has been developed in the African 
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subcontinent [20] but was developed specifically for outcome 
prediction during meningococcal outbreaks.
We have previously identified clinical predictors of death 
from adult ABM in Malawi [1]. In the present study, we grouped 
these outcome predictors to generate and validate a severity 
score nomogram for use in resource-poor settings. We used the 
validated score to analyze data from large placebo-controlled 
trials of adjunctive dexamethasone and glycerol in Malawi, to 
better understand why these treatments were ineffective.
PATIENTS AND METHODS
Patient Selection
Clinical data from the Malawi Meningitis Database (MMD) 
[1], and patient data from a recent clinical trial of goal-directed 
therapy (ISRCTN96218197) were used (Figure 1). All patients 
had been enrolled in clinical studies of adult ABM in Queen 
Elizabeth Central Hospital in Blantyre, Malawi, between 2000 
and 2013 (Figure 1). The inclusion criteria for the MMD were 
age >14 years with proven cerebrospinal fluid (CSF) infection 
on culture, polymerase chain reaction, or Gram stain of bacteria 
known to cause meningitis (proven meningitis), or appropri-
ate clinical history <5 days with a CSF white blood cell (WBC) 
count >50 cells/µL and >50% neutrophils (probable meningi-
tis). In human immunodeficiency virus (HIV)–coinfected indi-
viduals, the CSF WBC count threshold for probable meningitis 
was lowered to >5 cells/µL, (100% neutrophils), to include HIV-
coinfected individuals with low CD4 counts who mount a weak 
CSF inflammatory response in ABM [1, 4].
Cases were excluded if there was CSF evidence of Cryptococcus 
neoformans or Mycobacterium tuberculosis, CSF WBC count 
>50% lymphocytes with no documented prehospital antibiotics, 
or trial-specific exclusion criteria such as diabetes for the glyc-
erol trial [9, 10]. Diagnostic testing for viral meningitis was not 
available and is an uncommon cause of neurological infection in 
our center [21]. MMD patients randomized to receive glycerol 
were excluded from the nomogram development, as glycerol 
receipt was an independent predictor of poor outcome [10].
Ascertainment of Clinical Characteristics and Outcomes
All prospective clinical trial data were utilized with permission 
from the principal investigator. Individual study protocols were 
examined; only identical variables across the studies were col-
lected (data collected in the same units, at similar time points, 
using the same normal ranges). All studies were undertaken in the 
same hospital, using the same laboratories and similar case record 
forms. Physiological data are from the first recording to minimize 
both heterogeneity and biases associated with delays to antibiotic 
therapy, and increase applicability for clinical use in the region. 
Outcome was measured as death or survival at day 40 postadmis-
sion to account for additional acute postdischarge mortality, which 
has been reported to occur due to late complications in 5%–10% 
of initial survivors of ABM [9, 22]. Data on in-hospital delays and 
morbidity (principally deafness) were collected variably across the 
studies and were not included to minimize heterogeneity.
Ethical Approvals
All contributing clinical studies were granted ethical approval 
by the College of Medicine Research and Ethics Committee, 
University of Malawi, and the Liverpool School of Tropical 
Medicine Research Ethics Committee and conformed to insti-
tutional guidelines. All trial participants or named patient 
guardians provided written informed consent.
Selection of Predictor Variables
A literature search was performed to determine predictor vari-
ables for adults with bacterial meningitis [1]. Individual predic-
tors of mortality from the published analysis of the MMD (coma, 
seizures, anemia, and tachycardia) [1] and variables associated 
in other studies with poor outcome (age, sex, HIV status, CSF 
WBC count, and CSF culture) were finally used [7, 19, 23, 24].
Figure  1. Consolidated Standards of Reporting Trials (CONSORT) diagram 
demonstrating selection of data for the Malawi Meningitis Database.
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Statistical Methods, Derivation of the Nomogram, and Validation Methods
Data were summarized as follows: continuous normally dis-
tributed data using means and standard deviations, skewed 
data using medians and interquartile range, and categorical 
data using percentages. Analyses using a univariate logistic 
regression model were performed on all relevant covariates 
and factors to assess any association with day 40 outcome. The 
unadjusted estimates were reported using odds ratios (ORs) 
and 95% confidence intervals (CIs). Multivariable analyses fol-
lowed on the discovery cohort using a logistic regression model 
to assess factors and covariates independently associated with 
the day 40 outcome; this model included all variables with sta-
tistical significance on univariate analysis. Variables with high 
proportions (>50%) of missing data were excluded to reduce 
risks of overfitting. All analyses were performed using IBM 
SPSS software version 20.0 (IBM Statistics, Armonk, New York) 
and Stata software version 13.0 (StataCorp, College Station, 
Texas). Statistical significance was set at P < .05.
All variables with significance in the multivariable model 
were used to model the predictive tool, using R software version 
R-i386 3.0.3 (www.r-project.org) using rms package and the lrm 
and nomogram commands.
The developed model was validated to estimate the poten-
tial model performance. Because external data for validation 
have not yet been identified, an internal validation procedure 
was performed using bootstrapping (5000 samples), based on 
calibration, and discrimination [25, 26]. This procedure was 
selected to optimize the number of cases available while min-
imizing risks of overfitting.
A logistic regression model was used to obtain the predicted 
deaths. The Hosmer-Lemeshow C-statistic was used to assess 
calibration; low insignificant Hosmer-Lemeshow C-statistic 
indicated good fit [27]. The calibration assessment was supple-
mented by the use of a Brier score (range 0 and 1); an α value 
<.05 (5% significance level) was used to determine model fit [28, 
29]. A receiver operating characteristic (ROC) curve was plotted 
and used to calculate the validated concordance index (C-index). 
The ROC curve was obtained with the C-index (area under the 
curve [AUC]) and associated 95% CIs. The sensitivity and spec-
ificity of the model is based on a cutoff of 50% risk score. The 
individual Malawi Adult Meningitis Score (MAMS) was calcu-
lated for patients using IBM SPSS software version 20.0.
Analysis of Clinical Trial Data Using MAMS
The MAMS was calculated for all patients who had been 
recruited to clinical trials testing adjunctive dexamethasone 
and glycerol. Cases were risk stratified by quartile risk of poor 
outcome, and separated by placebo or intervention. Case fatal-
ity rate (CFRs) were calculated within each quartile group and 
compared to the predicted risk of poor outcome; statistical 
significance was determined using χ2 test. Data were analyzed 
using both original complete case and bootstrapped data.
RESULTS
Clinical Characteristics of the Patients
Data on patients meeting the inclusion criteria were available for 
607 ABM cases and were used for univariate analyses. Five hun-
dred ninety-three patients had CSF results available; of these, 
384 (65%) were CSF culture positive (Supplementary Table 1). 
Complete case data were available for 523 cases of bacterial 
meningitis, which were used for the multivariable analyses and 
development of the nomogram. Mean age was 32.5 years (SD, 
10.8 years), 50.7% (308/607) were female, 87% (506/584) were 
HIV coinfected, and 31% (171/551) had an acute seizure within 
the first 6 hours of admission. Presenting characteristics by out-
come group are detailed in Table 1.
The case fatality rate (CFR) was 44% (267/607) at day 10 and 
54% (320/593) at day 40. The following associations with death 
at day 40 were observed univariately in the discovery cohort 
(Table  1): age, temperature, low Glasgow Coma Scale (GCS), 
low oxygen saturation, high pulse rate, low CSF WBC count, 
and low hemoglobin level (Table 1). Other included variables 
showed no association with outcome on univariate analysis: sex, 
HIV serostatus, mean arterial blood pressure, respiratory rate, 
CSF culture, seizures, and blood glucose (Table 1).
All variables tested were included in the multivariable anal-
ysis model, with the exception of oxygen saturation, temper-
ature, and respiratory rate (>50% missing data) (Table 1). All 
variables with univariate significance, with the exception of age, 
also had an association with outcome on multivariable analysis 
(ORs per unit of measure change): GCS: OR, 0.77 [95% CI, .72–
.83], P < .001; pulse rate: OR, 1.01 [95% CI, 1.00–1.03], P = .01; 
log10 CSF WBC count: OR, 0.66 [95% CI, .53–.80], P < .001; and 
hemoglobin: OR, 0.84 [95% CI, .78–.90], P < .001.
Although CSF pneumococcal culture had no significant asso-
ciation with outcome on univariate analysis, the multivariable 
model demonstrated a significant association with survival 
(OR, 0.36 [95% CI, .23–.57], P < .001). Outcome data by organ-
ism (Supplementary Table 1) showed that increased mortality 
was observed in patients with nonpneumococcal meningitis. 
Although numbers were small, increased mortality in the non-
pneumococcal groups (CFR, 56.5% vs 51.5% for S.  pneumo-
niae) was correlated with lower GCS and thus associated with 
poor outcome in the multivariable model. The lack of signifi-
cant association with mortality on univariate analysis for the 
remainder of the variables, including HIV status, was retained 
on multivariable analysis.
Results of the Nomogram
Five variables strongly associated with day 40 mortality were 
used to develop the nomogram: GCS, pulse rate, CSF WBC 
count, pneumococcal culture, and hemoglobin level (Figure 2). 
To calibrate the nomogram, the continuous variables were cat-
egorized either by quartile around the median, or by standard 
normal clinical ranges. To optimize the nomogram, calibration 
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data derived from the categorical data were compared with con-
tinuous data [30]. Categorical data led to overfitting and poorer 
performance; therefore, the nomogram using continuous data 
is reported (Figure 2).
The database was subject to 5000 bootstraps, and the entire 
derivation process was then repeated using the bootstrapped 
data. The log (OR) and associated bootstrapped CIs are reported 
(Supplementary Table 2). The data show shrinkage factor (bias) 
used to adjust the estimated regression coefficients in the final 
model for overfitting. Supplementary Table 2 details the boot-
strapped CIs for estimated coefficients.
The corresponding ROC curve for the final nomogram is 
shown in Figure 3. The AUC was 0.76 (95% CI, .71–.80). The 
sensitivity of this model using a cutoff of 50% risk score is 71.7% 
(95% CI, 66.0%–76.9%) with a specificity of 63.1% (95% CI, 
56.7%–69.2%).
Calibration
Goodness-of-fit analysis was assessed to calibrate the nom-
ogram. Hosmer-Lemeshow C-statistic was χ2 =  5.48, df  =  8, 
P = .705. Calibration was good across individual centiles of esti-
mated mortality probability (Table 2). The Brier score was 0.2 
(95% bootstrap CI, .185–.215). Both the C-statistic and Brier 
score indicate good calibration. Discrimination was primar-
ily determined by the C-index (AUC). The observed C-index 
was 0.755 from the original sample; the optimism corrected or 
adjusted C-index (mean over 5000 bootstraps) was 0.760 (95% 
bootstrapped CI, .71–.79).
MAMS, the European Meningitis Score (EMS), and an older 
outcome score developed in the United States were all derived 
using similar methods. Therefore, when the C-index of MAMS 
was compared directly to the published C-index of these scores 
[18, 19, 31], MAMS was equivalent. When tested using Malawi 
data, the EMS C-index was 0.68 (95% CI, .63–.73), compared 
with the MAMS C-index of 0.76 (95% CI, .71–.80), suggesting 
that MAMS may be a better score than EMS in this setting.
Mortality Effects of Glycerol and Dexamethasone
Case fatality rate were compared by quartile of predicted risk 
in 2 clinical trials of dexamethasone and glycerol [9, 10]. In the 
Table 1. Results of the Univariate Analysis and Predictors of Outcome From the Complete Case Data
Parameter
Day 40 Univariate Analysis (Unadjusted) Multivariable Analysis (Adjusted)a
Alive Dead Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Sample size n = 607 273 320
Age, y, mean (SD) 31.5 (10.9) 32 (10.6) 1.01 (1.00–1.03) .01 1.00 (.95–1.06) .84
 >40 y 42 (14.6) 53 (16.6) 1.30 (.67–2.5) .42
Sex, male 136 (47) 163 (50.9) 1.17 (.85–1.62) .32
HIV status
 Infected 226 (78) 280 (87) 0.79 (.32–1.95) .61
 Unknown 10 (3.5) 13 (4.1)
Admission out of hours 122 (42.5) 139 (43.9) 1.20 (.68–1.28) .40
 Unknown 30 (10.5) 29 (9.1)
GCS, mean (SD) 12 (2.8) 9.9 (3.5) 0.82 (.78–.86) <.001 0.77 (.72–.83) <.001
Acute seizure episodes
 1 seizure 45 (16) 70 (22) 0.61 (.30–1.23) .16
 2 seizures 18 (6.3) 37 (11.6) 0.75 (.33–1.70) .49
Temperature, °C, mean (SD) 38.2 (1.1) 38.4 (1.3) 1.17 (1.02–1.34)b .02 c
SpO2, %, mean (SD) 95.5 (2.5) 96 (6.5) 0.90 (.82–1.00)
b .07 c
Pulse rate, beats/min, mean (SD) 98.6 (19) 104.8 (19.8) 1.01 (1.00–1.02)b <.001 1.01 (1.00–1.03) .01
MAP, mm Hg, mean (SD) 89.9 (15.1) 90.5 (16.7) 1.00 (.99–1.01) .81
Respiratory rate, breaths/min, mean 
(SD)
24.7 (6.6) 26.9 (7.9) 1.04 (.99–1.09)b .11 c
CSF WBC count, cells/µLd, median 
(IQR)
356 (64–1280) 215 (35–630) 0.49 (.37–.64)b <.001 0.66 (.53–.80) <.001
CSF culture positive for
 Streptococcus pneumoniae
160 (55) 165 (51.6) 1.06 (.66–17.1)b .96 0.36 (.23–.57) <.001
Plasma glucose, mmol/L, mean (SD) 7.5 (2.7) 7.6 (3.8) 1.00 (.95–1.05) .87 c
Hemoglobin, g/dL, mean (SD) 11.2 (2.6) 10.1 (2.6) 0.86 (.80–.91)b <.001 0.84 (.78–.90) <.001
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; HIV, human immunodeficiency virus; IQR, interquartile range; MAP, mean arterial pressure;   
SD, standard deviation; SpO2, Oxygen Saturations (%); WBC, white blood cell.
aPerformed on complete case data only (n = 523).
bOdds ratio for a unit change in predictor variable.
cProportion of missing data >50%, so variable was excluded from multivariable analysis.
dOdds ratios calculated on log10 data. Fifteen patients were CSF culture negative with CSF WBC count >50 cells/µL; an additional 6 were HIV coinfected white cell counts >5 cells/µL.
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dexamethasone study, an increased CFR was seen in the low-
est risk quartile, but no differences were observed in other risk 
quartiles (Table 3). In contrast, glycerol was associated with 
increased risk of death across all but the highest risk quartile 
in that study (Table 3). The same trends were observed when 
nonbootstrapped data were used, but were not statistically sig-
nificant (data not shown).
DISCUSSION
This analysis shows that estimation of mortality risk from bacte-
rial meningitis in adults in sub-Saharan Africa is possible using 
simple clinical parameters. MAMS is derived from communi-
ty-acquired meningitis data, from an African region with a high 
HIV prevalence and burden of adult bacterial meningitis. This 
score is therefore likely to be relevant to similar settings but not 
to regions where epidemics of both Neisseria meningitidis and 
S. pneumoniae occur seasonally [2, 6, 32]. We demonstrate the 
utility of MAMS in the assessment of clinical trials, showing 
that compared to placebo, adjunctive glycerol is associated with 
the greatest increased risk of death in those patients predicted 
to have a lower risk of poor outcome. The only other score 
published from Africa was derived in the Sahel region and, 
therefore, while applicable to settings with epidemic of menin-
gococcal meningitis [20], is of limited utility elsewhere.
We used similar data processes to develop MAMS as used 
in the EMS and a score developed in the United States [18, 19]. 
The EMS was developed on a discovery cohort of 691 patients 
[7] and underwent validation on 301 separate patients from the 
European Dexamethasone Study [33]. Patients receiving either 
dexamethasone or placebo were included and, interestingly, 
the authors comment that EMS performed better in those in 
receipt of dexamethasone who had better outcomes, compared 
with placebo [18, 33]. In the development of our score, we 
included patients who received dexamethasone, but excluded 
those receiving glycerol to minimize biases; glycerol was inde-
pendently associated with mortality in Malawi [1, 9, 10]. The 
C-index of MAMS falls within the 95% CI for the C-index of 
both the EMS and the US-based score, and therefore can be 
considered of equal strength as the other scores in their valida-
tion settings.
The EMS performed less well in an external validation exer-
cise, utilizing data from dexamethasone clinical trials from 
Vietnam and Malawi [9, 31, 34]. This may simply be due to dif-
fering methodology, including the use of categorized data in the 
EMS nomogram, and the selection of categorical cutoffs may 
have been less appropriate for these younger African patients 
[18]. However, we believe that the poorer performance of the 
EMS in those settings highlights critical differences between 
developed and developing country ABM populations, includ-
ing longer time to presentation, a higher prevalence of HIV 
and anemia, greater frequency of complications, and fewer 
resources available for clinical management [35, 36].
Figure  2. Malawi Adult Meningitis Score (MAMS) nomogram. A  variable is 
measured and its value is matched to the corresponding point on the first row of 
the nomogram. The points are then added for all 5 variables for each patient. The 
total points for the patient are matched to the corresponding risk score percentage 
at the bottom (ie, match up the 2 last rows of the nomogram). Abbreviations: CSF, 
cerebrospinal fluid; GCS, Glasgow Coma Scale; WBC, white blood cell count.
Figure  3. Receiver operating characteristic (ROC) curve for the Malawi Adult 
Meningitis Score (MAMS).
Table 2. Summary of the Agreement of the Nomogram per Risk Centile
Group
Probability 
Centile of 
Death
Observed  
Deaths,  
No. (%)
Predicted 
Deaths,  
No. (%) Total
1 0.234 6 (11.3) 9 (17.0) 53
2 0.326 14 (26.9) 15 (28.8) 52
3 0.389 23 (44.2) 19 (36.5) 52
4 0.460 24 (45.3) 22 (41.5) 53
5 0.540 25 (48.1) 26 (50.0) 52
6 0.604 30 (57.7) 30 (57.7) 52
7 0.677 30 (56.6) 34 (64.2) 53
8 0.763 40 (76.9) 37 (71.2) 52
9 0.836 42 (80.8) 42 (80.8) 52
10 0.962 45 (86.5) 46 (88.5) 52
Total 279 279 523
Hosmer-Lemeshow C-statistic, χ2 = 5.48, df = 8, P = .705.
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The original trial of adjunctive glycerol in Malawi was 
stopped early due to unexpected increase in mortality in the 
glycerol arm [10]. Why this effect occurred predominately 
in those with lower predicted risk of death as determined by 
MAMS is uncertain. However, we hypothesize that in less 
severely ill patients, glycerol-induced vasodilation of pial 
microarterioles and osmotic effects may decompensate fragile 
but balanced fluid compartments in the brain and the systemic 
circulation, with adverse effects on brain swelling and perfu-
sion [37, 38]. By comparison, in severely ill patients, breakdown 
of the blood–brain barrier is advanced; hence, glycerol has no 
additive adverse effect.
A major limitation in the development both of EMS and 
MAMS was missing data, managed using bootstrapping 
for both scores to reduce the risk of overfitting [18]. The 
developed model was validated to estimate the potential for 
overfitting and optimism in model performance using an 
internal validation procedure. This methodology is advised 
in the absence of external validation data, instead of use of 
split samples or cross-validation without replication [25, 
26]. The nomogram was optimized using standard valida-
tion exercises to reduce overlap, and high levels of agreement 
were observed. Cohort assembly was done using data from 
multiple studies in the same hospital; biases from interob-
server disagreement were minimized by only selecting varia-
bles that were collected uniformly across all studies. All data 
were collected prospectively in the same units, by research 
staff trained in the same institution, using the same equip-
ment to minimize potential biases associated with post hoc 
cohort assembly. We used data from the first recording after 
admission to hospital in all studies to minimize the effect of 
in-hospital delays on alterations on physiological variables 
that may otherwise affect the prognostic power of the score. 
Other limitations include use of data from only 1 country, 
relative infrequency of HIV-uninfected patients, lack of 
inclusion data on morbidity endpoints and processes of care 
including antibiotic delays, and relatively few patients with 
meningococcal vs pneumococcal meningitis [6]. The MAMS 
nomogram requires external prospective validation in other 
populations, including specific validation in countries at risk 
of epidemic meningococcal disease.
It is clear that in the development of a severity score, other 
factors beyond those measured in the score may be important 
in determining outcome of adults with bacterial meningitis in 
sub-Saharan Africa. Although HIV coinfection was not asso-
ciated with mortality and not included in the nomogram, it is 
possible that low CSF WBC count and low hemoglobin level 
may both correlate with advanced immunosuppression. CD4 
cell count data are currently lacking in this setting.
In conclusion, the MAMS risk stratification tool has a 
good predictive power for use in ABM in adults in sub-Sa-
haran Africa outside the epidemic meningitis belt. MAMS 
can be used in the analysis of prospective clinical trial data, 
testing efficacy of interventions in different risk groups. The 
differences between MAMS and EMS scores highlight impor-
tant differences between ABM patients in these contrasting 
environments. Further work is required to explore these dif-
ferences, to test MAMS prospectively, and to design optimal 
interventions to reduce the unacceptable mortality from men-
ingitis in Africa.
Table  3. Day 40 Mortality Outcomes From Dexamethasone and Glycerol Compared to Placebo by Malawi Adult Meningitis Score Risk Centile 
(Bootstrapped Data)
MAMS Risk Probability of Death 
at Day 40
Placebo 
(n = 1293)
Dexamethasone 
(n = 1268)
CFR% 
P ValueAlive, No.
Dead,
No. (CFR%) Alive, No.
Dead,
No. (CFR%)
<25% 61 0 (0) 48 6 (11) .010
25%–50% 232 106 (31) 236 126 (35) .330
50%–75% 252 311 (55) 173 264 (60) .100
>75% 66 265 (80) 99 316 (78) .210
Total 611 682 (53) 556 712 (56) .120
Placebo 
(n = 549)
Glycerol 
(n = 592)
CFR% Significance of CFR 
Intervention vs Placebo P ValueAlive, No.
Dead,
No. (CFR%) Alive, No.
Dead,
No. (CFR%)
<25% 51 6 (10) 49 14 (22) .080
25%–50% 112 31 (21) 85 92 (52) <.001
50%–75% 119 124 (51) 69 167 (70) <.001
>75% 18 88 (83) 29 87 (75) .140
Total 300 249 (45) 232 360 (61) .001
Abbreviations: CFR, case fatality rate; MAMS, Malawi Adult Meningitis Score.
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Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the author to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the author, so 
questions or comments should be addressed to the author.
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